Numinus Wellness Inc (OTCQB:NUMIF) has been approved to use psilocybin-assisted therapy through Health Canada’s Special Access Program (SAP), marking the first instance in which Numinus will provide this treatment outside of a clinical trial.
The newly approved treatment will be done at the company’s clinic in Montreal. Patients who take part in the SAP program must have a life-threatening condition in which conventional treatments have not functioned or are not available in the country.
